Keyphrases
Combination Trials
100%
Non-Hodgkin Lymphoma
100%
Oral Cyclophosphamide
100%
Interferon alpha-2b
100%
Favorable Histology
100%
Leukopenia
83%
Leukemia
66%
Prior Chemotherapy
66%
Previously Untreated Patients
66%
Chemotherapy
50%
Follicular non-Hodgkin Lymphoma
50%
Prior Cancer
50%
Remission Induction
33%
Partial Response
33%
Histology
16%
Early Response
16%
Patient Demographics
16%
Ploughing
16%
Lymphoma
16%
Anemia
16%
Life-threatening
16%
Thrombocytopenia
16%
Interferon-α (IFN-α)
16%
Previously Treated Patients
16%
Response Rate
16%
High Incidence
16%
Complete Response Rate
16%
Complete Response
16%
Drug Regimen
16%
Intron A
16%
Pathology Review
16%
Aggressive Histology
16%
Medicine and Dentistry
Non-Hodgkin Lymphoma
100%
Cyclophosphamide
100%
Interferon Alfa 2b
100%
Oral
100%
Leukopenia
83%
Malignant Neoplasm
66%
Patient History of Chemotherapy
66%
Leukemia
66%
Spontaneous Remission
33%
Leukocyte
16%
Patient Population
16%
Anemia
16%
Thrombocytopenia
16%
Recombinant Alpha2b Interferon
16%
Interferon
16%
Pharmacology, Toxicology and Pharmaceutical Science
Cyclophosphamide
100%
Nonhodgkin Lymphoma
100%
Alpha2b Interferon
100%
Leukopenia
83%
Leukemia
66%
Malignant Neoplasm
66%
Patient History of Chemotherapy
66%
Chemotherapy
50%
Remission
33%
Recombinant Alpha2b Interferon
16%
Anemia
16%
Interferon
16%
Thrombocytopenia
16%
Immunology and Microbiology
Alpha2b Interferon
100%
Cyclophosphamide
100%
Interferon Type I
16%
Leukocyte
16%
Recombinant Alpha2b Interferon
16%